JPMorgan Chase & Co. Reiterates “Overweight” Rating for Shire PLC (SHPG)
Shire PLC (NASDAQ:SHPG)‘s stock had its “overweight” rating restated by equities researchers at JPMorgan Chase & Co. in a research note issued to investors on Monday.
SHPG has been the subject of several other reports. Zacks Investment Research upgraded shares of Shire PLC from a “sell” rating to a “hold” rating in a research note on Thursday, August 4th. Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a research note on Tuesday, September 27th. Jefferies Group reiterated a “buy” rating and set a $262.00 price objective on shares of Shire PLC in a research note on Wednesday, September 7th. BTIG Research reiterated a “buy” rating and set a $230.00 price objective on shares of Shire PLC in a research note on Tuesday, July 12th. Finally, Leerink Swann reiterated a “buy” rating and set a $213.00 price objective on shares of Shire PLC in a research note on Tuesday, July 12th. Five equities research analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $228.15.
Shire PLC (NASDAQ:SHPG) traded down 1.02% during midday trading on Monday, hitting $185.79. The stock had a trading volume of 928,814 shares. The firm has a 50-day moving average of $194.68 and a 200 day moving average of $187.77. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The firm has a market capitalization of $55.34 billion, a P/E ratio of 38.61 and a beta of 1.16.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/jpmorgan-chase-co-reiterates-overweight-rating-for-shire-plc-shpg.html
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The company earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. Shire PLC had a net margin of 13.19% and a return on equity of 17.70%. Shire PLC’s revenue was up 55.9% compared to the same quarter last year. During the same period last year, the firm earned $2.63 earnings per share. On average, equities analysts forecast that Shire PLC will post $12.92 EPS for the current year.
The firm also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were paid a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s payout ratio is currently 15.63%.
A number of large investors have recently made changes to their positions in the company. Canal Insurance CO acquired a new stake in shares of Shire PLC during the second quarter valued at $102,000. FTB Advisors Inc. increased its stake in shares of Shire PLC by 3.1% in the second quarter. FTB Advisors Inc. now owns 600 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 18 shares during the last quarter. Duncker Streett & Co. Inc. acquired a new stake in shares of Shire PLC during the second quarter valued at $111,000. Quadrant Capital Group LLC increased its stake in shares of Shire PLC by 157.6% in the second quarter. Quadrant Capital Group LLC now owns 608 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 372 shares during the last quarter. Finally, Ropes Wealth Advisors LLC acquired a new stake in shares of Shire PLC during the second quarter valued at $114,000. 24.30% of the stock is currently owned by hedge funds and other institutional investors.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.